Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744966 | 0.84 | ADORA1 (0.75) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL16120984 | 0.83 | ADORA2B (0.81) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL18175139 | 0.83 | ADORA2B (0.71) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL17748272 | 0.82 | ADORA1 (0.76) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL10354149 | 0.81 | ADORA2B (0.68) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL10669551 | 0.81 | ADORA2B (0.66) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL16120979 | 0.81 | ADORA2B (0.85) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL19370573 | 0.81 | ADORA2B (0.71) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL16120975 | 0.81 | ADORA2B (0.88) | ADORA2BMAPTLMNARXFP1ADORA1 | |
| SCHEMBL4529535 | 0.80 | ADORA2B (0.76) | ADORA2BMAPTLMNARXFP1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4735959-A | HYPOGLYCEMIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1988-04-05 | — | — | US | disclosed |